AbbVie has increased its dividend by 5.2%, raised its earnings outlook, and delivered impressive growth from its two leading immunology drugs. But with shares trading near $289, substantial debt on the balance sheet, and an expensive acquisition strategy, dividend investors need to look beyond the latest payout increase. There is something reassuring about a company that keeps increasing its dividend. While Wall Street spends its days obsessing over artificial intelligence, economic forecasts, and whatever financial catastrophe happens to be fashionable this week, dividend investors tend to appreciate something considerably less complicated: a business that earns money and shares a portion of it with its owners. Unfortunately, a growing dividend does not automatically make a stock a good investment. That brings me to AbbVie (NYSE: ABBV), one of the more interesting dividend-growth stories in the pharmaceutical industry. On October 30, 2026, AbbVie announced that it would increase its q...
STOCK ANALYSIS | DIVIDEND INVESTING | NOVEMBER 2, 2026 Altria keeps raising prices, growing earnings, and sending shareholders their quarterly checks. Unfortunately, its customers are increasingly looking at Marlboro's premium prices and deciding their loyalty has a spending limit. NYSE: MO Q3 2026 Earnings Analysis Adjusted Q3 EPS $1.52 +4.8% YoY Annual dividend $4.44 +4.7% Discount share 34.1% +2.0 pp YoY Source: Altria's October 29, 2026 third-quarter earnings release. Altria Group, Inc.+1 Altria Raised Its Dividend Again—But One-Third of Smokers Are Now Buying Discount Cigarettes By Tony Hicks | November 2, 2026 There's something almost admirable about a company that can sell fewer products every year, charge increasingly outrageous prices for the remaining ones, and somehow convince Wall Street that everything is going according to plan. Welcome to Altria Group (NYSE: MO), where the customer base keeps shrinking, the prices keep climbing, and shareholders continue coll...